With chronic kidney disease, the kidneys gradually lose their ability to function over time. It is a serious condition that affects approximately 30 million adults in the U.S.
Understanding chronic kidney disease
The kidneys are responsible for filtering waste and excess fluids from the blood by secreting them into your urine. When your kidneys are unable to complete this task, electrolytes and waste can build up in the body.
Chronic kidney disease, also known as CKD, often has no signs when it’s in the earliest stages. As such, the condition may not be diagnosed until it is advanced and kidney function has declined significantly.
What causes CKD?
CKD develops when another disease or condition negatively impacts the kidneys. This often occurs with the following diagnoses:
- Type 1 and type 2 diabetes
- Enlarged prostate
- High blood pressure
- Kidney stones
- Certain cancers
- Interstitial nephritis
- Vesicoureteral reflux
- Polycystic kidney disease
- Recurrent kidney infection
Current Treatment Options
Treatment plans for chronic kidney disease are complex and multi-faceted. The objectives are typically to manage the symptoms, prevent complications and slow the progression of the disease.
Once you reach end-stage kidney disease, the organs can no longer remove waste and fluid on their own. When this occurs, you will need dialysis or a kidney transplant. Fortunately, new treatments are emerging that may help more patients slow the progression of the disease and avoid these potentially fatal complications.
Study: A new treatment approach for Anemia associated with chronic kidney disease
At Unison, we are actively recruiting qualified participants for a study evaluating the efficacy of oral and injectable medications for chronic kidney disease / anemia. If you are interested and available, and you meet the qualifications outlined below, please contact us today.
- Length of trial: 4 years or longer
- Age range: 18 years or older
- Chronic kidney disease stage 3, 4 or 5
- Hgb 8-12 g/dl (5-7.3 mmol/L) if on erythropoietin stimulating agents (ESAs)
- OR Hgb 8-10 g/dl (5-6.2 mmol/L if not using erythropoietin stimulating agents (ESAs)
- Treatment: The efficacy of oral or injectable medications. These treatments will be randomly assigned to each group of participants.
All of our clinical trials are free of cost. No medical insurance is necessary and you may be compensated for your participation.
Are you Eligible?
If you're interested in participating in one of our upcoming clinical trials, please join our patient database today. After reviewing your information, we will contact you to schedule a consultation if you qualify for a study.